Previous Article | Next Article 
Journal of Clinical Microbiology, September 2001, p. 3303-3310, Vol. 39, No. 9
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.9.3303-3310.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Evaluation of Recombinant Leptospira Antigen-Based
Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of
Leptospirosis
Brendan
Flannery,1
Dirceu
Costa,2
Fernanda Pinheiro
Carvalho,2
Hygia
Guerreiro,2,3
James
Matsunaga,4,5
Emilson
Domingos
Da Silva,6
Antonio Gomes
Pinto
Ferreira,6
Lee W.
Riley,1
Mitermayer G.
Reis,2
David A.
Haake,4,5 and
Albert I.
Ko2,7,*
School of Public Health, University of California,
Berkeley, California 947201;
Gonçalo Moniz Research Center, Oswaldo Cruz Foundation,
Brazilian Ministry of Health,2 and
School of Pharmacy, Federal University of
Bahia,3 Salvador, Brazil; Division
of Infectious Diseases, Veterans Affairs Greater Los Angeles Healthcare
System, Los Angeles, California 900734;
Department of Medicine, UCLA School of Medicine, Los Angeles,
California 900955; Biomanguinhos,
Oswaldo Cruz Foundation, Brazilian Ministry of Health, Rio de Janeiro,
Brazil6; and Division of
International Medicine and Infectious Disease, Weill Medical College
of Cornell University, New York, New York
100217
Received 26 February 2001/Returned for modification 28 May
2001/Accepted 1 July 2001
 |
ABSTRACT |
There is an urgent need for development of new serodiagnostic
strategies for leptospirosis, an emerging zoonosis with
worldwide distribution. We have evaluated the diagnostic utility of
five recombinant antigens in enzyme-linked
immunosorbent assays (ELISAs) for serodiagnosis of leptospirosis. Sera
from 50 healthy residents of a high-incidence region were used to
determine cutoff values for 96% specificity. In paired sera from 50 cases of leptospirosis confirmed by the microscopic agglutination test,
immunoglobulin G (IgG) but not IgM reacted with the recombinant
leptospiral proteins. The recombinant LipL32 IgG ELISA had the highest
sensitivities in the acute (56%) and convalescent (94%) phases of
leptospirosis. ELISAs based on recombinant OmpL1, LipL41, and Hsp58 had
sensitivities of 16, 24, and 18% during the acute phase and 72, 44, and 32% during convalescence, respectively. Compared to sera from
healthy individuals, patient sera did not react significantly with
recombinant LipL36 (P > 0.05). Recombinant LipL32
IgG ELISA demonstrated 95% specificity among 100 healthy individuals,
and specificities ranging from 90 to 97% among 30 dengue patients, 30 hepatitis patients, and 16 patients with diseases initially thought to
be leptospirosis. Among 39 Venereal Disease Research Laboratory
test-positive individuals and 30 Lyme disease patients, 13 and
23% of sera, respectively, reacted positively with the
rLipL32 antigen. These findings indicate that
rLipL32 may be an useful antigen for the serodiagnosis of leptospirosis.
 |
INTRODUCTION |
Leptospirosis is a zoonosis
caused by pathogenic spirochetes of the genus Leptospira.
Although traditionally considered an occupational risk among persons
exposed to contaminated water or infected animal urine (15,
16), leptospirosis is becoming recognized as a common cause of
febrile illness in tropical environments worldwide (5, 14,
38). Awareness of its public health importance has increased
following recent reports of outbreaks associated with recreational
exposures (7-9) and emerging epidemics of
leptospirosis-associated severe pulmonary hemorrhage syndrome
(28, 33, 35, 40, 49). Leptospirosis has now expanded to
affect urban populations throughout Latin America and the Caribbean.
Epidemics associated with high case fatality (greater than 15%) break
out annually during seasonal periods of heavy rainfall in poor urban
areas that lack basic sanitation infrastructure (23, 26).
During these outbreaks, confusion between the broad spectrum of
clinical presentations associated with leptospirosis and classic dengue fever (24, 37) complicates the early diagnosis required
for the timely administration of antibiotic therapy. The need for rapid
and appropriate diagnostic tests has become ever more urgent to aid
clinical case identification and to facilitate the implementation of
rapid outbreak investigations.
The standard serologic test, the microscopic agglutination test (MAT),
is inadequate for rapid case identification since it can only be
performed in a few reference laboratories and requires analyses of
paired sera to achieve sufficient sensitivity (12, 15).
Dependence upon the MAT results in delays in establishing the cause of
outbreaks, as seen in several investigations (7, 47).
Enzyme-linked immunosorbent assays (ELISAs) (12, 46, 48),
and other rapid serologic tests based on whole-cell leptospiral antigen
preparations (43, 44, 50) have been developed for use as
an alternative method to screen for leptospiral infection, although the
MAT is still required for case confirmation (12, 15).
Recombinant-antigen-based serologic tests are widely used in screening
for spirochetal infections such as Lyme disease and syphilis (17,
22, 27, 39), but the use of recombinant proteins for
serodiagnosis of leptospirosis has not been widely investigated.
Recently, a recombinant flagellar antigen immunocapture assay was
described for serodiagnosis of bovine leptospirosis (6). A
recombinant heat shock protein, Hsp58, showed a high degree of ELISA
reactivity with serum samples from a small number of human cases
(32). However, the utility of recombinant antigens for the
serodiagnosis of human leptospirosis has not been investigated in large
validation studies.
In a previous study, we identified leptospiral antigens that were
serodiagnostic markers of infection in immunoblot analyses (18). A 32-kDa protein was identified to be an
immunodominant antigen with the best serodiagnostic utility: 38 and
85% of cases of leptospirosis had detectable antibodies during the
acute and convalescent phases, respectively, of their illness.
Anti-32-kDa protein reactivity was detected in less than 5% of sera
from control individuals. This antigen was identified as LipL32, a
major leptospiral outer membrane protein whose expression is restricted
to pathogenic Leptospira species (20). Hsp58, a
member of the GroEL family of heat shock proteins, was also identified
in immunoblots with human sera and was the antigen recognized most
frequently by patient antibodies in the acute phase of the illness. Two
membrane proteins, the porin OmpL1 (19) and
lipoprotein LipL41 (41), were identified as immunoreactive
proteins, but the frequency of seroreactivity could not be
determined due to the limited resolution of the native proteins on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. The characterization of these leptospiral
proteins makes it possible to express and purify recombinant fusion
proteins in a form suitable for diagnostic formats such as
recombinant-antigen ELISA. The present study was conducted to
evaluate the utility of these recombinant proteins from
Leptospira as antigens in ELISAs.
 |
MATERIALS AND METHODS |
Patient and control individuals.
Fifty paired sera were
randomly selected from a bank of samples from more than 300 laboratory-confirmed cases identified during active hospital-based
surveillance from March 1996 to October 1997 for urban epidemics of
leptospirosis in the city of Salvador, Brazil. The MAT and culture
isolation were performed for laboratory confirmation of leptospirosis
as previously described (23). The first, "acute-phase"
serum sample from these patients was collected during hospital
admission, a median of 7 days (range. 2 to 23 days) after reported
onset of symptoms. A second, "convalescent-phase" serum sample was
collected following discharge, a median of 29.5 days (range, 17 to 113 days) after the reported onset of symptoms. The case definition for MAT
confirmation was a fourfold rise in MAT titer between paired sera or a
single serum MAT titer of >1:800. The highest agglutinating titers for
49 (98%) of the 50 patients were to reference strains of the serogroup
Icterohaemorrhagiae. In addition to MAT, culture isolation and
whole-Leptospira immunoglobulin M (IgM) ELISA were performed
with patient samples. Among 14 patients who had a blood culture
performed upon hospital admission, Leptospira interrogans
serovar copenhageni was isolated from 7 (50%). The IgM
whole-Leptospira ELISA was performed as described by Adler et al. (1) with sonicated antigen from a clinical isolate
of L. interrogans serovar copenhageni (23). A
positive reaction in IgM ELISA was defined as an absorbance value
greater than that of the cutoff reference sample, which corresponded to
the 98th percentile absorbance value among sera of healthy control
individuals from an endemic region.
Control serum samples were obtained from 100 healthy individuals and
136 patients with diseases other than leptospirosis. Serum samples from
healthy individuals (n = 50) in Salvador, Brazil, a
region of high leptospirosis incidence, were randomly selected from a
serum bank collected during a city-wide serosurvey for infectious
diseases performed in 1998. In addition, serum samples from healthy
individuals (n = 50) from Northern California (gift of
Michael Hendry, California State Department of Health, Berkeley, Calif.) were obtained as control sera from a region of low
leptospirosis incidence. Patient sera were analyzed from the following
control groups: cases of Lyme disease (n = 30) from the
United States(gift of Martin Schriefer, Centers for Disease Control and
Prevention, Fort Collins, Colo.) and four patient groups from Salvador,
Brazil: Venereal Disease Research Laboratory (VDRL)
test-positive individuals (n = 30; samples
obtained from the Central Laboratory for the State of Bahia, Brazil
[LACEN/BA]), laboratory-confirmed (dengue IgM ELISA) cases of dengue
(n = 30; obtained from LACEN/BA), patients with acute
hepatitis B virus infection (hepatitis B S-antigen positive;
n = 30; obtained from LACEN/BA), and patients who were hospitalized with an initial clinical suspicion of leptospirosis and
subsequently diagnosed as having another illness based on laboratory or
radiological evidence (n = 16). Serum samples were aliquoted after collection and stored at
20°C.
Recombinant Leptospira antigens.
The pRSET
plasmid (Invitrogen) constructs containing portions of genes encoding
the leptospiral outer membrane proteins LipL32, OmpL1, and LipL41 were
prepared as described previously (19, 20, 41). The
previously described recombinant LipL36 (21) was included
in the analysis as a control antigen because the expression of
lipoprotein LipL36 is downregulated during infection, and therefore
reactivity of patient sera is expected to be minimal. The PCR-amplified
genes were ligated into the pRSET plasmid for expression as recombinant
His6 fusion proteins. The 1,641-bp DNA fragment
of the hsp58 coding region was obtained from PCR
amplification of genomic DNA of an L. interrogans serovar
copenhageni clinical isolate (23) with primers
corresponding to the N-terminal and C-terminal sequences of a published
sequence (GenBank accession number L14682) (2). The
hsp58 fragment was inserted into the pQE30 expression vector
(Qiagen) and electroporated into Escherichia coli M15 pREP4
cells (Qiagen).
Isopropyl-
-D-thiogalactopyranoside (IPTG; 2 mM final
concentration; Life Technologies) was added to log-phase cultures of E. coli BLR(DE3)pLysS (Novagen) transformed with pRSET
plasmids encoding leptospiral genes for expression of
His6 fusion proteins rLipL32, rOmpL1,
rLipL41, rLipL36, and rHsp58. For outer membrane proteins, 6 M guanidine was used to solubilize culture pellets. His6 fusion proteins were purified by affinity
chromatography with Ni2+-nitrilotriacetic
acid-agarose (Qiagen). The purity of eluted His6
fusion proteins was assessed by gel electrophoresis and staining with
Coomassie brilliant blue. Proteins were dialyzed overnight against
phosphate-buffered saline (PBS)-10% (vol/vol) glycerol-0.025% (wt/vol) sodium azide-0.1 to 0.3% (vol/vol) Triton X-100. After dialysis, the protein concentration was determined with bicinchoninic acid (42). Recombinant outer membrane proteins were then
diluted 10- to 15-fold in buffer without Triton X-100. The culture
pellet containing rHsp58 was suspended in 50 mM sodium phosphate
buffer, cells were lysed with sonification, and rHsp58 was purified
under native conditions with
Ni2+-nitrilotriacetic acid-agarose (Qiagen).
After dialysis against 0.1 M PBS, the concentrations of fusion proteins
were determined using the DC Protein Assay (Bio-Rad).
Recombinant-antigen ELISAs.
Flat-bottomed polystyrene
microtiter plates (Corning) were coated at 4°C overnight with
His6 fusion proteins, 0.5 to 100 ng/well, suspended in 0.05 M sodium carbonate (pH 9.6). The plates were washed
twice with distilled water and three times with PBS-0.05% (vol/vol)
Tween 20 (PBST). Plates were incubated with blocking solution (PBST
with 1% [wt/vol] bovine serum albumin) for 2 h at room
temperature and, after four washes with PBST, stored at
20°C until
use. Wells were incubated with 50 µl of sera, diluted 25- to 200-fold
in blocking solution, for 1 h at room temperature with agitation.
After four washes with PBST, wells were incubated with 50 µl of
5,000- to 20,000-fold dilutions of antihuman µ- or
-chain goat
antibodies conjugated to horseradish peroxidase (Sigma) for 1 h at
room temperature with agitation. Afterwards, plates were washed twice
with PBST and three times with PBS and incubated with 50 µl/well
of 0.01% (wt/vol) 3,3',5,5'-tetramethylbenzidine in substrate buffer
(0.03% [vol/vol] hydrogen peroxide, 25 mM citric acid, 50 mM
Na2HPO4 [pH 5.0]) for 20 min in the dark at room temperature. The color reaction was
stopped by adding 25 µl of 2 N
H2SO4, and the absorbance
at 450 nm was measured in an Emax microplate reader (Molecular Devices,
Sunnyvale, Calif.).
Initial assays were performed to determine the antigen concentration
that best discriminated between ELISA reactions of serum samples from
confirmed leptospirosis cases with reciprocal MAT titers greater than
800 (n = 8) and healthy individuals from a nonendemic
area for leptospirosis in the United States (n = 4). Checkerboard titrations were performed with 25-, 50-, 100-, or 200-fold
serum dilutions and antigen concentrations per well of 5, 25, 50, and
100 ng. In subsequent assays to determine sensitivity and specificity,
plates were coated with the predetermined antigen concentrations.
Incubations were performed with 50- and 20,000-fold dilutions of
primary sera and secondary antibody conjugate, respectively. Individual
serum samples were tested in duplicate, and the means of the two
measurements were calculated for analysis. Paired measurements that
differed by greater than 10% were retested. One positive control serum
sample which reacted with all recombinant antigens and one negative
control serum sample were included, in duplicate, on each plate as a
quality control measure.
Statistical analyses.
Data were analyzed in Graph Pad Prism
software (version 3.0; San Diego, Calif.). A cutoff value for each
recombinant-antigen ELISA was defined as the 96th percentile of
absorbance values among serum samples (n = 50) from
Brazilian control individuals who reside in regions endemic for
leptospirosis. Sensitivity was defined as the percentage of
laboratory-confirmed cases of leptospirosis whose serum samples had
mean absorbance of duplicate samples greater than the cutoff value.
Specificity was calculated as the percentage of control individuals
whose samples had mean absorbance below the cutoff value. The
Mann-Whitney test was used to compare the median absorbance values for
serum samples from leptospirosis cases with those from healthy
individuals. Among confirmed cases of leptospirosis, the Wilcoxon
ranked sign test for matched pairs was used to determine whether median
optical density (OD) values of convalescent-phase sera were
significantly different from those of acute-phase sera. The
2 test with Yates' correction was used to
compare proportions of positive ELISA reactions.
 |
RESULTS |
Standardization of recombinant-antigen ELISAs.
Five
leptospiral antigens were expressed as His6
fusion proteins and purified by affinity chromatography. Prior to use
in ELISAs, recombinant antigens were tested in immunoblots: pooled sera
from leptospirosis cases had strong reactions to rLipL32 and
rHsp58 and moderate reactions to OmpL1 and LipL41 and did not react
with rLipL36 (data not shown). In initial ELISAs, the mean
absorbance values among selected case sera were significantly higher
than those of a sample of healthy U.S. individuals (P < 0.05), demonstrating IgG antibody reactivity to all five recombinant leptospiral proteins. IgM antibody reactivity was not detected in case
or control samples to the three antigens, rLipL32, rHsp58, and rOmpL1, for which this response was evaluated. The performance of
three representative recombinant IgG ELISAs at different antigen concentrations and serum dilutions is shown (Fig.
1). Sample absorbance in the rHsp58 IgG
ELISA was positively correlated with increasing antigen concentration
from 5 to 100 ng/well in a dose-dependent manner (Fig. 1). In contrast,
maximum absorbance values were observed at a concentration of 25 ng/well in the rLipL32 ELISA, while absorbance decreased with
increasing antigen concentrations above 5 ng/well in the rOmpL1 ELISA.
A similar phenomenon was observed for recombinant membrane-associated
proteins rLipL41 and rLipL36 and appeared to be
associated with the concentration of Triton X-100 used to solubilize
these recombinant proteins. Antigen preparations with reduced detergent
concentrations had increased mean absorbances for case and control
samples at all antigen concentration points (data not shown). At the
lowest concentration of Triton X-100 used to solubilize recombinant
proteins other than rHsp58, maximum absorbance values could be observed
at the antigen concentrations of 25 ng/well or greater. In subsequent
assays to determine sensitivity and specificity, a concentration of 5 ng/well was used for rLipL32, rLipL41, and
rLipL36 ELISAs, while 25 ng/well was used for rHsp58 and
rOmpL1 ELISAs. The ratio of mean absorbance values between case and
control individual samples was not significantly different at 50-, 100-, and 200-fold dilutions of primary antisera, and therefore a
50-fold dilution was chosen for subsequent assays.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Performance of IgG ELISA at different serum sample
dilutions and recombinant protein concentrations. Results are shown for
assays with three selected recombinant leptospiral proteins, rHsp58
(left), rLipL32 (center), and rOmpL1 (right). For each point,
a mean absorbance value (OD450 on the vertical axis) and
standard deviation were plotted for serum samples from eight patients
with confirmed leptospirosis (solid line) or four healthy control
individuals (dashed line). Reactions for wells coated with
5, 25, 50, or 100 ng of recombinant antigen are represented
on the horizontal axis. Plates were incubated with sera that were
diluted 50- (first row), 100- (second row), or 200- (third row) fold.
|
|
Determination of cutoff values.
Serum samples
(n = 50) from Brazilian control individuals who reside
in a region endemic for leptospirosis were tested in parallel with
samples from confirmed cases. The 96th percentile of absorbance values
among samples from endemic region control individuals was defined as
the cutoff value to achieve a diagnostic specificity of 96% (Fig.
2). Absorbance values among these control samples varied depending on the recombinant-antigen ELISA. The range of
OD450 values for the rOmpL1 ELISA (0.008 to
0.705) was 10 times greater than the range of values
observed for the rLipL32 ELISA (0.002 to 0.071). The defined
cutoff value was five times higher for the rOmpL1 ELISA
(OD450 = 0.247) than for the rLipL32 ELISA (OD450 = 0.050) (Table
1). Cutoff values for recombinant-antigen ELISAs are shown in Table 1. For four of the recombinant-protein ELISAs, median absorbance values of control samples from healthy U.S.
individuals from a nonendemic region did not differ significantly from
those of healthy Brazilian individuals from a high-incidence region.
The one exception was the rHsp58 ELISA, in which the median value for
endemic-area sera was 1.6 times higher than the median for nonendemic
control sera (P < 0.01).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
IgG antibody responses in leptospirosis patients and
control groups to recombinant leptospiral proteins as determined by
ELISA. Results are shown for three selected recombinant antigens, at
concentrations of 25 ng of antigen per well (rHsp58 and rOmpL1) or 5 ng
of antigen per well (rLipL32). Absorbance (OD450)
values are shown for reactions with serum samples, diluted 50-fold,
from healthy individuals in an endemic region for leptospirosis in
Salvador, Brazil (group A, ), or a nonendemic U.S. region (group B,
) compared to paired serum samples from 50 patients with confirmed
leptospirosis from Salvador, Brazil (group C, acute-phase or group
D, convalescent-phase ). Fifty samples were tested in each group.
Median absorbance values for each group of samples are shown as solid
lines. The cutoff value, defined as the absorbance value for the 96th
percentile of the group of 50 serum samples from healthy control
individuals from Salvador, Brazil, are represented as dashed lines.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
IgG antibody reactivity of serum samples from patients
with leptospirosis and control groups against five leptospiral
His6 fusion proteins as determined by ELISA
|
|
Sensitivity of recombinant-antigen IgG ELISAs.
The
rLipL32 ELISA demonstrated the highest sensitivity in
acute- and convalescent-phase serum samples (56 and 94%,
respectively) from confirmed cases of leptospirosis (Table 1 and
Fig. 2). Other recombinant-antigen ELISAs demonstrated less than 30%
sensitivity to detect leptospiral infection in the acute phase of
illness. In convalescent-phase serum samples, the sensitivity of the
rOmpL1 ELISA increased to 72%, while the rLipL41 and rHsp58
assays had sensitivities of 44 and 32%, respectively. Less than 20%
of case serum samples had detectable antibody against
rLipL36, a lipoprotein that is produced at low levels during
infection, although the median serum absorbance values did increase
significantly between the acute and convalescent phase of disease
(median OD450, 0.044 versus 0.071;
P < 0.05).
Combining results of the rHsp58 and rLipL32 ELISAs increased
sensitivity from 56 to 64% in acute-phase sera, with a corresponding decrease in diagnostic specificity from 95 to 92%. Combinations of
results from other recombinant-antigen ELISAs did not further increase
the sensitivity for detecting leptospiral infection in acute-phase samples.
Specificity of recombinant-antigen IgG ELISAs in control patient
groups.
Reactivities of antibodies from dengue, hepatitis, Lyme,
and VDRL test-positive patients were not determined for
rLipL36 since overall sensitivity was less than 20%. Percent
reactivity among patient control groups did not differ significantly
from community-based control groups from Brazil or the U.S. in ELISAs
with rLipL32, rHsp58, rOmpL1, and rLipL41 (Table
1). Exceptions included Lyme disease patients in the rLipL32
assay, of whom seven (23%) had serum absorbance values above the
cutoff (versus five [5%] healthy individuals), and hepatitis
patients and VDRL test-positive individuals in the rLipL41
assay, of whom 10 (30%) and 11 (33%), respectively, had serum
absorbance above the cutoff (versus 6 [7%] healthy individuals). Among patients with diseases initially suspected as being
leptospirosis, 2 of the 16 patients in the first group were responsible
for outlying values (greater than twice the cutoff value) in the
rLipL32 ELISA; both of these patients had an invasive
bacterial infection (sepsis or pneumonia).
rLipL32 IgG ELISA versus standard diagnostic tests.
The positivity of the rLipL32 IgG ELISA in acute-phase
samples increased from 36% (10 of 28) during the first week (
7 days) of symptoms to 86% (18 of 21) after the first week of symptoms (8 to
23 days) (Table 2). LipL32 seropositivity
was not detected in five samples obtained in the first 4 days of
illness.
The results of the rLipL32 IgG ELISA were compared with those
of the MAT for the 50 confirmed cases of leptospirosis (Table 2). At
the time of hospital admission, the rLipL32 IgG ELISA had
greater sensitivity (56 versus 42%) than MAT positivity at a
100-fold serum dilution, a commonly used criterion for screening for
leptospiral infection. Among acute-phase samples, 12 (24%) that tested
positive in the rLipL32 ELISA had undetectable
agglutination reactions in the MAT, while 5 (10%) that had reciprocal
MAT titers greater than or equal to 100 had negative rLipL32
ELISA results. For samples collected from MAT-confirmed leptospirosis
cases in the convalescent phase of illness following discharge from the hospital, 47 (94%) of 50 had positive absorbance values in the rLipL32 IgG ELISA. A positive reaction in the
rLipL32 assay was observed in one sample obtained
from a patient 113 days after the onset of disease.
For acute-phase samples, culture isolation was negatively associated
with rLipL32 ELISA absorbance value (P = 0.011). None of the seven samples from culture-positive cases were
seroreactive in the rLipL32 assay, whereas six of seven
(86%) from culture-negative cases were seroreactive. All
culture-positive patient samples had undetectable MAT agglutination
titers in the acute phase of the disease.
In the whole-Leptospira IgM ELISA, 26 (54%) acute-phase
samples and 47 (98%) convalescent-phase samples were positive among the 48 patients tested. The whole-Leptospira IgM and IgG
rLipL32 ELISAs demonstrated similar kinetics of reactivity in
the first 2 weeks after the onset of illness (Table 2). Both IgM and
rLipL32 IgG ELISAs were positive in 19 (40%) of 48 patients
at the time of hospital admission, while 7 (15%) were only IgM
positive, and 8 (17%) were only rLipL32 IgG positive.
 |
DISCUSSION |
Improved diagnostic tests for leptospirosis are urgently
needed to aid clinical diagnosis in the initial phase of the
disease and for rapid case confirmation during outbreak surveillance. Doxycycline therapy initiated soon after the onset of symptoms can
prevent severe complications and deaths (15, 31). However, diagnosis during this critical period requires a high index of suspicion, as early symptoms are often indistinguishable from those of
dengue fever and other febrile illnesses (24, 37). Efforts
to develop new diagnostic tests to achieve high sensitivity in the
acute phase have focused primarily on detecting IgM binding to
whole-cell antigen preparations. The immunodominant moiety in
whole-cell preparations appears to be a broadly reactive antigen (15, 46) that is a disaccharide epitope present in
nonpathogenic leptospires as well as a diverse group of nonleptospiral
species (29, 30). IgM ELISAs (12, 48),
dipstick assays (25, 43, 44, 50), and simple agglutination
assays (25, 45) appear to have variable sensitivities of
35 to 85% for serum samples collected in the first 10 days of illness
from cases subsequently confirmed by MAT, in evaluations performed in
different sites (Table 3) (43,
44).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Comparison of results of serodiagnostic tests for
leptospirosis from selected validation studies with the rLipL32
ELISA
|
|
Recombinant protein-based serologic tests may achieve high sensitivity
and specificity because of the high concentration of immunoreactive
antigens which can be used in assays and the lack of nonspecific
moieties present in whole-cell preparations. An ideal antigen would be
a principal target of the host immune response, expressed only in
pathogenic Leptospira spp. and conserved among the more than
200 serovars associated with human disease in different geographic
regions and epidemiological situations (15). An ideal test
will need to discriminate between leptospirosis and a broad spectrum of
diseases that cause acute febrile illnesses and have overlapping
clinical presentations. Because the burden of leptospirosis is greatest
in developing countries (15), there is a need to develop a
test which can be produced at low cost and easily standardized for use
in field settings.
In the present study, five recombinant leptospiral proteins were
evaluated as antigens in ELISAs. The rLipL32 ELISA
demonstrated the highest sensitivity: it detected IgG antibodies in 56 and 94% of the MAT-confirmed cases of leptospirosis during the acute and convalescent phases of illness, respectively. LipL32, the most
prominent protein in the SDS-PAGE total protein profile
(20) and the major outer membrane protein
(51), was also the most frequently recognized antigen in
immunoblots with patient sera (18). Whereas anti-LipL32
IgG reactivity was detected in samples collected from patients within
the first 8 days of illness and this response correlated with the
duration of symptoms, no anti-LipL32 IgM reactivity was detected in any
acute- or convalescent-phase samples.
The diagnostic specificity of the rLipL32 IgG ELISA was 95%
for healthy individuals living in regions of high and low leptospirosis incidence. The low background reactivity may be due, in part, to the
restricted expression of LipL32 in pathogenic leptospires (20) and not saprophytic forms that are ubiquitous in the
environment. The rLipL32 ELISA appears to differentiate
patients with leptospirosis from those with other important causes of
acute jaundice and febrile illnesses, such as dengue and hepatitis,
since specificity in these groups was greater than 90%. Higher
antibody reactivities in VDRL-positive and Lyme disease patients (13 and 23% reactivity, respectively) suggests that there may be
cross-reactive epitopes in other spirochetes, including
Borrelia and Treponema spp., which were not
detected in BLAST homology searches (20).
After the rLipL32 ELISA, the two assays with the highest
sensitivities were those based on rOmpL1 and rLipL41. Like
LipL32, OmpL1 and LipL41 are found only in pathogenic
Leptospira (19, 41) and are expressed by the
pathogen during experimental infection (3). Triton X-100,
used to maintain the solubility of these membrane-associated proteins,
appeared to interfere with the binding of these antigens, as with
LipL32, to ELISA plates, and reducing its concentration increased the
sensitivity for these assays. In the present evaluation, the
recombinant Hsp58 assay showed lower IgG reactivity than reported
previously (32 versus 82%) (32). A high cutoff threshold
was necessary to obtain greater than 95% specificity for the
rHsp58 IgG ELISA. The dominant epitope in leptospiral Hsp58
is a 20-amino-acid sequence highly conserved among prokaryotic GroEL
homologues (32). The observed background reactivity to
recombinant Hsp58 may have contributed to the high cutoff value for
this assay and lower sensitivity. In the present study, combinations of
the results of other assays with those of the rLipL32 assay
did not increase the sensitivity of ELISA for MAT-confirmed cases.
The robust IgG and undetectable IgM response to recombinant leptospiral
proteins during early illness is surprising. However, there does exist
precedence for this phenomenon in leptospirosis: several studies have
documented IgG immunoblot reactivity to leptospiral proteins during
acute-phase illness in the absence of specific IgM antibodies
(10, 11, 18). Traditionally, IgM antibodies, directed
primarily against carbohydrate epitopes (15), have been
believed to be the predominant humoral response during
acute-phase infection (1, 46). In this study,
such a response was detected in whole-Leptospira ELISAs.
Remarkably, the IgG response to rLipL32 and other recombinant
antigens was found to have kinetics comparable to that of the IgM
response to whole-antigen preparations. The rapid rise in IgG antibody
may have been due to a memory response in individuals with prior
exposure to leptospires. Alternatively, this could represent a rapid
IgM-to-IgG class-switch phenomenon, since it appears unlikely
that the relatively large proportion of patients who seroconverted in
both whole-Leptospira IgM and rLipL32 IgG ELISAs
were previously exposed. Together, these findings suggest that early
host immune response to Leptospira infection is
characterized by both IgM and IgG antibodies specific for different moieties, as observed in the early response to Borrelia
(13, 27) and Treponema infection
(39).
Our findings indicate that recombinant LipL32 may be an appropriate
antigen for serodiagnosis in field settings. The rLipL32 ELISA demonstrated sensitivity comparable to currently available rapid
screening tests in the acute phase and high sensitivity for
MAT-confirmed cases in the convalescent phase (Table 3). Although whole
Leptospira antigen can be used in serodiagnostic tests to
detect either IgM or IgG antibodies (1, 46), extensive quality control measures are necessary to monitor batch-to-batch variability in antigen composition inherent in growing large
cultures of Leptospira (15).
Recombinant-antigen-based assays may circumvent this problem and
furthermore may be produced at lower cost, an important consideration
for implementation in developing countries.
One potential limitation to the use of this test in case confirmation
is the persistence the anti-LipL32 IgG response after acute
infection. In this study, seropositivity was detected in samples
obtained up to 113 days after the onset of symptoms. The duration of
seropositivity in ELISAs will need to be evaluated further in
longitudinal studies of the host IgG response. However, the criterion
for positivity used in the recombinant-antigen ELISA was a cutoff
absorbance value which gave 98% specificity in community control
groups from the same epidemic region as cases. Furthermore, the
specificity of this cutoff was >90% for patient
control groups from the same region. Therefore, the response
to LipL32 may not be prolonged enough to interfere with the application
of this test in epidemiologic and clinical situations associated with recurrent urban epidemics.
The conserved nature and high level of expression of LipL32 among
pathogenic Leptospira spp. (20) suggest that
the rLipL32 ELISA may exhibit similar performance
regardless of the locally predominant serovar agent. Sera used in
the present evaluation were from patients residing in regions in
which the most prevalent Leptospira serovar is copenhageni,
the etiologic agent of urban epidemics throughout Brazil (4, 23,
34, 36). Validation studies in geographical regions with a
spectrum of etiologic serovars will be helpful in assessing
whether the rLipL32 ELISA can be widely applied. Furthermore,
recombinant LipL32 can be incorporated in rapid formats, such as
dipstick, to facilitate its use in serodiagnosis in developing countries.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from Biomanguinhos, Oswaldo
Cruz Foundation, Brazilian Ministry of Health (09224-7), the Brazilian
National Research Council (521.229/98-7, 300.861/96-6; 350.052/95-6,
and FINEP 4196086200), VA Medical Research Funds, and the National
Institutes of Health (AI-01605, AI-34431, TW-00905, and TW-00919).
We thank Mary Mazel and Tracy Young (Division of Infectious Diseases,
West Los Angeles Veterans Affairs Medical Center) for preparation of
the recombinant membrane-associated leptospiral proteins; and Fernanda
Carvalho Pinheiro, Patrícia Guimarães Oliveira, Suzana
Ramos Ferrer (Gonçalo Moniz Research Center, Oswaldo Cruz
Foundation), and Kátia Salgado (Couto Maia Hospital, Secretary of
Health for the State of Bahia) for technical assistance in collection
of sera from patients and laboratory confirmation of leptospirosis.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centro de
Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Rua
Waldemar Falcão, 121, 40295-001 Salvador, Brazil. Phone: (55 71)
356-4320, ext. 243. Fax: (55 71) 356-2155. E-mail:
aik2001{at}med.cornell.edu.
 |
REFERENCES |
| 1.
|
Adler, B.,
A. M. Murphy,
S. A. Locarnini, and S. Faine.
1980.
Detection of specific antileptospiral immunoglobulins M and G in human serum by solid-phase enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
11:452-457[Abstract/Free Full Text].
|
| 2.
|
Ballard, S. A.,
R. P. Segers,
N. Bleumink-Pluym,
J. Fyfe,
S. Faine, and B. Adler.
1993.
Molecular analysis of the hsp (groE) operon of Leptospira interrogans serovar copenhageni.
Mol. Microbiol.
8:739-751[Medline].
|
| 3.
|
Barnett, J. K.,
D. Barnett,
C. A. Bolin,
T. A. Summers,
E. A. Wagar,
N. F. Cheville,
R. A. Hartskeerl, and D. A. Haake.
1999.
Expression and distribution of leptospiral outer membrane components during renal infection of hamsters.
Infect. Immun.
67:853-861[Abstract/Free Full Text].
|
| 4.
|
Barocchi, M. A.,
A. I. Ko,
S. R. Ferrer,
M. T. Faria,
M. G. Reis, and L. W. Riley.
2001.
Identification of new repetitive element in Leptospira interrogans serovar copenhageni and its application to PCR-based differentiation of Leptospira serogroups.
J. Clin. Microbiol.
39:191-195[Abstract/Free Full Text].
|
| 5.
|
Bounlu, K.,
S. Insisiengmay,
K. Vanthanouvong,
Saykham,
S. Widjaja,
K. Iinuma,
K. Matsubayashi,
K. Laras,
M. Putri,
T. Endy,
D. Vaughn,
B. Raengsakulrach,
K. Hyams,
M. Hayden,
C. Scheffel, and A. Corwin.
1998.
Acute jaundice in Vientiane, Lao People's Democratic Republic.
Clin. Infect. Dis.
27:717-721[Medline].
|
| 6.
|
Bughio, N. I.,
M. Lin, and O. P. Surujballi.
1999.
Use of recombinant flagellin protein as a tracer antigen in a fluorescence polarization assay for diagnosis of leptospirosis.
Clin. Diagn. Lab. Immunol.
6:599-605[Abstract/Free Full Text].
|
| 7.
|
Centers for Disease Control.
1998.
Outbreak of acute febrile illness among athletes participating in triathlons Wisconsin and Illinois, 1998.
Morb. Mortal. Wkly. Rep.
47:585-588[Medline].
|
| 8.
|
Centers for Disease Control.
2000.
Outbreak of acute febrile illness among participants in EcoChallenge Sabah 2000 Malaysia, 2000.
Morb. Mortal. Wkly. Rep.
49:816-817.
|
| 9.
|
Centers for Disease Control.
1997.
Outbreak of leptospirosis among white-water rafters-Costa Rica, 1996.
Morb. Mortal. Wkly. Rep.
46:577-579[Medline].
|
| 10.
|
Chapman, A. J.,
B. Adler, and S. Faine.
1988.
Antigens recognised by the human immune response to infection with Leptospira interrogans serovar hardjo.
J. Med. Microbiol.
25:269-278[Abstract].
|
| 11.
|
Chapman, A. J.,
C. O. Everard,
S. Faine, and B. Adler.
1991.
Antigens recognized by the human immune response to severe leptospirosis in Barbados.
Epidemiol. Infect.
107:143-155[Medline].
|
| 12.
|
Cumberland, P.,
C. O. Everard, and P. N. Levett.
1999.
Assessment of the efficacy of an IgM-elisa and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis.
Am. J. Trop. Med. Hyg.
61:731-734[Abstract].
|
| 13.
|
Engstrom, S. M.,
E. Shoop, and R. C. Johnson.
1995.
Immunoblot interpretation criteria for serodiagnosis of early lyme disease.
J. Clin. Microbiol.
33:419-427[Abstract].
|
| 14.
|
Everard, C. O.,
C. N. Edwards,
J. D. Everard, and D. G. Carrington.
1995.
A twelve-year study of leptospirosis on Barbados.
Eur. J. Epidemiol.
11:311-320[CrossRef][Medline].
|
| 15.
|
Faine, S.,
B. Adler,
P. Perolat, and C. A. Bolin.
1999.
Leptospira and leptospirosis, 2nd ed.
MediSci, Melbourne, Australia.
|
| 16.
|
Farr, R. W.
1995.
Leptospirosis.
Clin. Infect. Dis.
21:1-6[Medline].
|
| 17.
|
Goossens, H. A. T.,
A. E. van der Bogaard, and M. K. E. Nohlmans.
1999.
Evaluation of fifteen commercially available serologic tests for diagnosis of lyme borreliosis.
Eur. J. Clin. Microbiol. Infect. Dis.
18:551-560[CrossRef][Medline].
|
| 18.
|
Guerreiro, H.,
J. Croda,
B. Flannery,
M. Mazel,
J. Matsunaga,
M. G. Reis,
P. N. Levett,
A. I. Ko, and D. A. Haake.
2001.
Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans.
Infect. Immun.
69:4958-4968[Abstract/Free Full Text].
|
| 19.
|
Haake, D. A.,
C. I. Champion,
C. Martinich,
E. S. Shang,
D. R. Blanco,
J. N. Miller, and M. A. Lovett.
1993.
Molecular cloning and sequence analysis of the gene encoding OmpL1, a transmembrane outer membrane protein of pathogenic Leptospira spp.
J. Bacteriol.
175:4225-4234[Abstract/Free Full Text].
|
| 20.
|
Haake, D. A.,
G. Chao,
R. L. Zuerner,
J. K. Barnett,
D. Barnett,
M. Mazel,
J. Matsunaga,
P. N. Levett, and C. A. Bolin.
2000.
The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection.
Infect. Immun.
68:2276-2285[Abstract/Free Full Text].
|
| 21.
|
Haake, D. A.,
C. Martinich,
T. A. Summers,
E. S. Shang,
J. D. Pruetz,
A. M. McCoy,
M. K. Mazel, and C. A. Bolin.
1998.
Characterization of leptospiral outer membrane lipoprotein LipL36: downregulation associated with late-log-phase growth and mammalian infection.
Infect. Immun.
66:1579-1587[Abstract/Free Full Text].
|
| 22.
|
Hauser, U., and B. Wilske.
1997.
Enzyme-linked immunosorbent assays with recombinant internal flagellin fragments derived from different species of Borrelia burgdorferi sensu lato for the serodiagnosis of Lyme neuroborreliosis.
Med. Microbiol. Immunol.
186:145-151[CrossRef][Medline].
|
| 23.
|
Ko, A. I.,
M. Galvao Reis,
C. M. Ribeiro Dourado,
W. D. Johnson, Jr.,
L. W. Riley, and the Salvador Leptospirosis Study Group.
1999.
Urban epidemic of severe leptospirosis in Brazil.
Lancet
354:820-825[Medline].
|
| 24.
|
Levett, P. N.,
S. L. Branch, and C. N. Edwards.
2000.
Detection of dengue infection in patients investigated for leptospirosis in Barbados.
Am. J. Trop. Med. Hyg.
62:112-114[Abstract].
|
| 25.
|
Levett, P. N.,
S. L. Branch,
C. U. Whittington,
C. N. Edwards, and H. Paxton.
2001.
Two methods for rapid serological diagnosis of acute leptospirosis.
Clin. Diagn. Lab. Immunol.
8:349-351[Abstract/Free Full Text].
|
| 26.
|
Lomar, A.,
D. Diament, and J. Torres.
2000.
Leptospirosis in Latin America.
Infect. Dis. Clin. North Am.
14:23-39[CrossRef][Medline].
|
| 27.
|
Magnarelli, L. A.,
J. W. Ijdo,
S. J. Padula,
R. A. Flavelli, and E. Fikrig.
2000.
Serologic diagnosis of Lyme borreliosis by using enzyme-linked immunosorbent assays with recombinant antigens.
J. Clin. Microbiol.
38:1735-1739[Abstract/Free Full Text].
|
| 28.
|
Marotto, P. C.,
C. M. Nascimento,
J. Eluf-Neto,
M. S. Marotto,
L. Andrade,
J. Sztajnbok, and A. C. Seguro.
1999.
Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality.
Clin. Infect. Dis.
29:1561-1563[CrossRef][Medline].
|
| 29.
|
Matsuo, K.,
E. Isogai, and Y. Araki.
2000.
Occurrence of [ 3)- -D-Manp-(1-4)- -D-Manp-(1 ]n units in the antigenic polysaccharides from Leptospira biflexa serovar patoc strain Patoc I.
Carbohydr. Res.
328:517-524[CrossRef][Medline].
|
| 30.
|
Matsuo, K.,
E. Isogai, and Y. Araki.
2000.
Utilization of exocellular mannan from Rhodotorula glutinis as an immunoreactive antigen in diagnosis of leptospirosis.
J. Clin. Microbiol.
38:3750-3754[Abstract/Free Full Text].
|
| 31.
|
McClain, J. B.,
W. R. Ballou,
S. M. Harrison, and D. L. Steinweg.
1984.
Doxycycline therapy for leptospirosis.
Ann. Intern. Med.
100:696-698.
|
| 32.
|
Park, S. H.,
B. Y. Ahn, and M. J. Kim.
1999.
Expression and immunologic characterization of recombinant heat shock protein 58 of Leptospira species: a major target antigen of the humoral immune response.
DNA Cell Biol.
18:903-910[CrossRef][Medline].
|
| 33.
|
Park, S. K.,
S. H. Lee,
Y. K. Rhee,
S. K. Kang,
K. J. Kim,
M. C. Kim,
K. W. Kim, and W. H. Chang.
1989.
Leptospirosis in Chonbuk Province of Korea in 1987: a study of 93 patients.
Am. J. Trop. Med. Hyg.
41:345-351.
|
| 34.
|
Pereira, M. M.,
M. G. Matsuo,
A. R. Bauab,
S. A. Vasconcelos,
Z. M. Moraes,
G. Baranton, and I. Saint Girons.
2000.
A clonal subpopulation of Leptospira interrogans sensu stricto is the major cause of leptospirosis outbreaks in Brazil.
J. Clin. Microbiol.
38:450-452[Abstract/Free Full Text].
|
| 35.
|
Rios-Goncalves, A. J.,
D. Capone,
N. A. Paz,
R. V. V. Paulo,
T. B. C. M. Dias,
V. C. C. Lago, and L. M. A. Carvalho.
1990.
Leptospirosis: observations on changes in clinical manifestations in Rio de Janeiro during a large epidemic in 1988.
Arq. Bras. Med.
64:389-397.
|
| 36.
|
Sakata, E. E.,
P. H. Yasuda,
E. C. Romero,
M. V. Silva, and A. V. Lomar.
1992.
The serovars of Leptospira interrogans isolated from cases of human leptospirosis in Sao Paulo, Brazil.
Rev. Inst. Med. Trop. Sao Paulo
34:217-221[Medline].
|
| 37.
|
Sanders, E. J.,
J. G. Rigau-Perez,
H. L. Smits,
C. C. Deseda,
V. A. Vorndam,
T. Aye,
R. A. Spiegel,
R. S. Weyant, and S. L. Bragg.
1999.
Increase of leptospirosis in dengue-negative patients after a hurricane in Puerto Rico in 1966.
Am. J. Trop.Med. Hyg.
61:399-404.
|
| 38.
|
Sasaki, D. M.,
L. Pang,
H. P. Minette,
C. K. Wakida,
W. J. Fujimoto,
S. J. Manea,
R. Kunioka, and C. R. Middleton.
1993.
Active surveillance and risk factors for leptospirosis in Hawaii.
Am. J. Trop. Med. Hyg.
48:35-43.
|
| 39.
|
Schmidt, B. L.,
M. Edjlalipour, and A. Luger.
2000.
Comparitive evaluation of nine different enzyme-linked immunosorbent assays for determination of antibodies against Treponema pallidum in patients with primary syphilis.
J. Clin. Microbiol.
38:1279-1282[Abstract/Free Full Text].
|
| 40.
|
Sehgal, S. C.,
M. V. Murhekar, and A. P. Sugunan.
1995.
Outbreak of leptospirosis with pulmonary involvement in north Andaman.
Indian J. Med. Res.
102:9-12[Medline].
|
| 41.
|
Shang, E. S.,
T. A. Summers, and D. A. Haake.
1996.
Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic Leptospira species.
Infect. Immun.
64:2322-2330[Abstract].
|
| 42.
|
Smith, P. K.,
R. I. Krohn,
G. T. Hermanson,
A. K. Mallia,
F. H. Gartner,
M. D. Provenzano,
E. K. Fujimoto,
N. M. Goeke,
B. J. Olson, and D. C. Klenk.
1985.
Measurement of protein using bicinchoninic acid.
Anal. Biochem.
150:76-85[CrossRef][Medline].
|
| 43.
|
Smits, H. L.,
Y. V. Ananyina,
A. Chereshsky,
L. Dancel,
A. F. R. F. Lai,
H. D. Chee,
P. N. Levett,
T. Masuzawa,
Y. Yanagihara,
M. A. Muthusethupathi,
E. J. Sanders,
D. M. Sasaki,
H. Domen,
C. Yersin,
T. Aye,
S. L. Bragg,
G. C. Gussenhoven,
M. G. Goris,
W. J. Terpstra, and R. A. Hartskeerl.
1999.
International multicenter evaluation of the clinical utility of a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human serum specimens.
J. Clin. Microbiol.
37:2904-2909[Abstract/Free Full Text].
|
| 44.
|
Smits, H. L.,
R. A. Hartskeerl, and W. J. Terpstra.
2000.
International multi-centre evaluation of a dipstick assay for human leptospirosis.
Trop. Med. Int. Health
5:124-128[CrossRef][Medline].
|
| 45.
|
Smits, H. L.,
M. A. van der Hoorn,
M. G. Goris,
G. C. Gussenhoven,
C. Yersin,
D. M. Sasaki,
W. J. Terpstra, and R. A. Hartskeerl.
2000.
Simple latex agglutination assay for rapid serodiagnosis of human leptospirosis.
J. Clin. Microbiol.
38:1272-1275[Abstract/Free Full Text].
|
| 46.
|
Terpstra, W. J.,
G. S. Ligthart, and G. J. Schoone.
1985.
ELISA for the detection of specific IgM and IgG in human leptospirosis.
J. Gen. Microbiol.
131:377-385[Medline].
|
| 47.
|
Trevejo, R. T.,
J. G. Rigau-Perez,
D. A. Ashford,
E. M. McClure,
C. Jarquin-Gonzalez,
J. J. J. Amador,
O. de los Reyes,
A. Gonzalez,
S. R. Zaki,
W. J. Shieh,
R. G. McLean,
R. S. Nasci,
R. S. Weyant,
C. A. Bolin,
S. L. Bragg,
B. A. Perkins, and R. A. Spiegel.
1998.
Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995.
J. Infect. Dis.
178:1457-1463[CrossRef][Medline].
|
| 48.
|
Winslow, W. E.,
D. J. Merry,
M. L. Pirc, and P. L. Devine.
1997.
Evaluation of a commercial enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody in diagnosis of human leptospiral infection.
J. Clin. Microbiol.
35:1938-1942[Abstract].
|
| 49.
|
Yersin, C.,
P. Bovet,
F. Merien,
J. Clement,
M. Laille,
M. Van Ranst, and P. Perolat.
2000.
Pulmonary haemorrhage as a predominant cause of death in leptospirosis in Seychelles.
Trans. R. Soc. Trop. Med. Hyg.
94:71-76[CrossRef][Medline].
|
| 50.
|
Yersin, C.,
P. Bovet,
H. L. Smits, and P. Perolat.
1999.
Field evaluation of a one-step dipstick assay for the diagnosis of human leptospirosis in the Seychelles.
Trop. Med. Int. Health
4:38-45[CrossRef][Medline].
|
| 51.
|
Zuerner, R. L.,
W. Knudtson,
C. A. Bolin, and G. Trueba.
1991.
Characterization of outer membrane and secreted proteins of Leptospira interrogans serovar pomona.
Microb. Pathog.
10:311-322[CrossRef][Medline].
|
Journal of Clinical Microbiology, September 2001, p. 3303-3310, Vol. 39, No. 9
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.9.3303-3310.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hauk, P., Macedo, F., Romero, E. C., Vasconcellos, S. A., de Morais, Z. M., Barbosa, A. S., Ho, P. L.
(2008). In LipL32, the Major Leptospiral Lipoprotein, the C Terminus Is the Primary Immunogenic Domain and Mediates Interaction with Collagen IV and Plasma Fibronectin. Infect. Immun.
76: 2642-2650
[Abstract]
[Full Text]
-
Verma, A., Rathinam, S. R., Priya, C. G., Muthukkaruppan, V. R., Stevenson, B., Timoney, J. F.
(2008). LruA and LruB Antibodies in Sera of Humans with Leptospiral Uveitis. CVI
15: 1019-1023
[Abstract]
[Full Text]
-
Doungchawee, G., Kositanont, U., Niwetpathomwat, A., Inwisai, T., Sagarasaeranee, P., Haake, D. A.
(2008). Early Diagnosis of Leptospirosis by Immunoglobulin M Immunoblot Testing. CVI
15: 492-498
[Abstract]
[Full Text]
-
McBride, A. J. A., Santos, B. L., Queiroz, A., Santos, A. C., Hartskeerl, R. A., Reis, M. G., Ko, A. I.
(2007). Evaluation of Four Whole-Cell Leptospira-Based Serological Tests for Diagnosis of Urban Leptospirosis. CVI
14: 1245-1248
[Abstract]
[Full Text]
-
Matsunaga, J., Lo, M., Bulach, D. M., Zuerner, R. L., Adler, B., Haake, D. A.
(2007). Response of Leptospira interrogans to Physiologic Osmolarity: Relevance in Signaling the Environment-to-Host Transition. Infect. Immun.
75: 2864-2874
[Abstract]
[Full Text]
-
Croda, J., Ramos, J. G. R., Matsunaga, J., Queiroz, A., Homma, A., Riley, L. W., Haake, D. A., Reis, M. G., Ko, A. I.
(2007). Leptospira Immunoglobulin-Like Proteins as a Serodiagnostic Marker for Acute Leptospirosis. J. Clin. Microbiol.
45: 1528-1534
[Abstract]
[Full Text]
-
Branger, C., Chatrenet, B., Gauvrit, A., Aviat, F., Aubert, A., Bach, J. M., Andre-Fontaine, G.
(2005). Protection against Leptospira interrogans Sensu Lato Challenge by DNA Immunization with the Gene Encoding Hemolysin-Associated Protein 1. Infect. Immun.
73: 4062-4069
[Abstract]
[Full Text]
-
Palaniappan, R. U.M., Chang, Y.-F., Hassan, F., McDonough, S. P., Pough, M., Barr, S. C., Simpson, K. W., Mohammed, H. O., Shin, S., McDonough, P., Zuerner, R. L., Qu, J., Roe, B.
(2004). Expression of leptospiral immunoglobulin-like protein by Leptospira interrogans and evaluation of its diagnostic potential in a kinetic ELISA. J Med Microbiol
53: 975-984
[Abstract]
[Full Text]
-
Haake, D. A., Suchard, M. A., Kelley, M. M., Dundoo, M., Alt, D. P., Zuerner, R. L.
(2004). Molecular Evolution and Mosaicism of Leptospiral Outer Membrane Proteins Involves Horizontal DNA Transfer. J. Bacteriol.
186: 2818-2828
[Abstract]
[Full Text]
-
Priya, C. G., Bhavani, K., Rathinam, S. R., Muthukkaruppan, V. R.
(2003). Identification and evaluation of LPS antigen for serodiagnosis of uveitis associated with leptospirosis. J Med Microbiol
52: 667-673
[Abstract]
[Full Text]
-
Haake, D. A., Matsunaga, J.
(2002). Characterization of the Leptospiral Outer Membrane and Description of Three Novel Leptospiral Membrane Proteins. Infect. Immun.
70: 4936-4945
[Abstract]
[Full Text]
-
Cullen, P. A., Cordwell, S. J., Bulach, D. M., Haake, D. A., Adler, B.
(2002). Global Analysis of Outer Membrane Proteins from Leptospira interrogans Serovar Lai. Infect. Immun.
70: 2311-2318
[Abstract]
[Full Text]
-
Matsunaga, J., Young, T. A., Barnett, J. K., Barnett, D., Bolin, C. A., Haake, D. A.
(2002). Novel 45-Kilodalton Leptospiral Protein That Is Processed to a 31-Kilodalton Growth-Phase-Regulated Peripheral Membrane Protein. Infect. Immun.
70: 323-334
[Abstract]
[Full Text]